230
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

, , , , , & show all
Pages 303-313 | Received 25 Nov 2022, Accepted 14 Feb 2023, Published online: 27 Feb 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (3)